公开(公告)号：EP3551225A1

公开(公告)日：2019-10-16

申请号：EP17818020.4

申请日：2017-12-07

申请人： Agenus Inc. ,  Ludwig Institute for Cancer Research Ltd ,  Memorial Sloan Kettering Cancer Center

发明人： VAN DIJK, Marc ,  MUNDT, Cornelia Anne ,  RITTER, Gerd ,  SCHAER, David ,  WOLCHOK, Jedd David ,  MERGHOUB, Taha ,  WILSON, Nicholas Stuart ,  SAVITSKY, David Adam ,  FINDEIS, Mark Arthur ,  ZAPPASODI, Roberta ,  HOLMGAARD, Rikke Bæk ,  CUILLEROT, Jean-Marie ,  PROSCURSHIM, Igor ,  SHEBANOVA, Olga

IPC分类号： A61K39/395 ,  C07K16/28

公开(公告)号：EP4289484A3

公开(公告)日：2024-03-06

申请号：EP23190631.4

申请日：2017-12-07

申请人： Agenus Inc. ,  Ludwig Institute for Cancer Research Ltd. ,  Memorial Sloan-Kettering Cancer Center

发明人： VAN DIJK, Marc ,  MUNDT, Cornelia Anne ,  RITTER, Gerd ,  SCHAER, David ,  WOLCHOK, Jedd David ,  MERGHOUB, Taha ,  WILSON, Nicholas Stuart ,  SAVITSKY, David Adam ,  FINDEIS, Mark Arthur ,  UNDERWOOD, Dennis John ,  CUILLEROT, Jean-Marie ,  PROSCURSHIM, Igor ,  SHEBANOVA, Olga

IPC分类号： C07K16/28 ,  A61K39/00 ,  A61P11/00 ,  A61P35/04

摘要： The instant disclosure provides antibodies that specifically bind to CTLA-4 (e.g., human CTLA-4) and antagonize CTLA-4 function. Also provided are pharmaceutical compositions comprising these antibodies, nucleic acids encoding these antibodies, expression vectors and host cells for making these antibodies, and methods of treating a subject using these antibodies.

公开(公告)号：EP4289484A2

公开(公告)日：2023-12-13

申请号：EP23190631.4

申请日：2017-12-07

申请人： Agenus Inc. ,  Ludwig Institute for Cancer Research Ltd. ,  Memorial Sloan-Kettering Cancer Center

发明人： VAN DIJK, Marc ,  MUNDT, Cornelia Anne ,  RITTER, Gerd ,  SCHAER, David ,  WOLCHOK, Jedd David ,  MERGHOUB, Taha ,  WILSON, Nicholas Stuart ,  SAVITSKY, David Adam ,  FINDEIS, Mark Arthur ,  UNDERWOOD, Dennis John ,  CUILLEROT, Jean-Marie ,  PROSCURSHIM, Igor ,  SHEBANOVA, Olga

IPC分类号： A61P35/04

摘要： The instant disclosure provides antibodies that specifically bind to CTLA-4 (e.g., human CTLA-4) and antagonize CTLA-4 function. Also provided are pharmaceutical compositions comprising these antibodies, nucleic acids encoding these antibodies, expression vectors and host cells for making these antibodies, and methods of treating a subject using these antibodies.

公开(公告)号：EP3736290A1

公开(公告)日：2020-11-11

申请号：EP20168222.6

申请日：2016-05-27

申请人： Agenus Inc. ,  Memorial Sloan-Kettering Cancer Center ,  Ludwig Institute for Cancer Research Ltd.

发明人： Van DIJK, Marc ,  MUNDT, Cornelia Anne ,  RITTER, Gerd ,  SCHAER, David ,  WOLCHOK, Jedd David ,  MERGHOUB, Taha ,  SAVITSKY, David Adam ,  FINDEIS, Mark Arthur ,  WILSON, Nicholas S

IPC分类号： C07K16/28

摘要： The instant disclosure provides antibodies that specifically bind to human CTLA-4 and antagonize CTLA-4 function. Also provided are pharmaceutical compositions comprising these antibodies, nucleic acids encoding these antibodies, expression vectors and host cells for making these antibodies, and methods of treating a subject using these antibodies.

公开(公告)号：EP3498295A1

公开(公告)日：2019-06-19

申请号：EP18204948.6

申请日：2015-05-28

申请人： Agenus Inc. ,  Memorial Sloan-Kettering Cancer Center ,  Ludwig Institute for Cancer Research Ltd

发明人： UNDERWOOD, Dennis J. ,  LÉGER, Olivier ,  SEIBERT, Volker ,  VAN DIJK, Marc ,  SCHAER, David ,  TSUJI, Takemasa ,  RITTER, Gerd ,  GONZALEZ, Ana M. ,  WILSON, Nicholas S. ,  ZAPPASODI, Roberta ,  MEGHOUB, Taha ,  WOLCHOK, Jedd David

IPC分类号： A61K39/395 ,  C07K16/28

摘要： The present disclosure provides antibodies that specifically bind to human glucocorticoid-induced TNFR family related receptor (GITR) and compositions comprising such antibodies. In a specific aspect, the antibodies specifically bind to human GITR and modulate GITR activity, e . g ., enhance, activate or induce GITR activity, utilizing such antibodies. The present disclosure also provides methods for treating disorders, such as cancer and infectious diseases, by administering an antibody that specifically binds to human GITR and modulates GITR activity e . g ., enhances, activates or induces GITR activity.

公开(公告)号：EP3148579A1

公开(公告)日：2017-04-05

申请号：EP15729987.6

申请日：2015-05-28

申请人： Agenus Inc. ,  Memorial Sloan Kettering Cancer Center ,  Ludwig Institute for Cancer Research Ltd

发明人： UNDERWOOD, Dennis J. ,  LEGER, Olivier ,  SIEBERT, Volker ,  VAN DIJK, Marc ,  SCHAER, David ,  TSUJI, Takemasa ,  RITTER, Gerd ,  GONZALEZ, Ana M. ,  WILSON, Nicolas S. ,  ZAPPASODI, Roberta ,  MERGHOUB, Taha ,  WOLCHOK, Jedd David

IPC分类号： A61K39/395 ,  C07K16/28

CPC分类号： C07K16/2878 ,  A61K35/17 ,  A61K2039/507 ,  C07K16/2809 ,  C07K2317/24 ,  C07K2317/34 ,  C07K2317/56 ,  C07K2317/565 ,  C07K2317/75 ,  C07K2317/76 ,  C07K2317/92 ,  G01N33/502 ,  G01N2333/70578

摘要： The present disclosure provides antibodies that specifically bind to human glucocorticoid-induced TNFR family related receptor (GITR) and compositions comprising such antibodies. In a specific aspect, the antibodies specifically bind to human GITR and modulate GITR activity, e.g., enhance, activate or induce GITR activity, utilizing such antibodies. The present disclosure also provides methods for treating disorders, such as cancer and infectious diseases, by administering an antibody that specifically binds to human GITR and modulates GITR activity e.g., enhances, activates or induces GITR activity.

摘要翻译： 本公开提供了特异性结合人类糖皮质激素诱导的TNFR家族相关受体（GITR）的抗体和包含此类抗体的组合物。 在具体方面，所述抗体与所述抗体特异性结合人GITR并调节GITR活性，例如增强，激活或诱导GITR活性。 本公开还提供了通过施用特异性结合人GITR并调节GITR活性的抗体（例如增强，激活或诱导GITR活性）来治疗疾病如癌症和感染性疾病的方法。